CADTH | pCODR PAN-CANADIAN ONCOLOGY DRUG REVIEW

PROVINCIAL FUNDING SUMMARY

Rydapt (Midostaurin) for Acute Myeloid Leukemia (pCODR 10108)

pERC Recommendation: Recommends

For further details, please see pERC Final Recommendation

Notification to Implement Issued by pCODR: January 11, 2018

This information is current as of March 1, 2020.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Under provincial consideration		
AB	Funded	Jan 29, 2019	In combination with standard cytarabine and anthracycline (such as daunorubicin or idarubicin) induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FMS-like tyrosine kinase 3 (FLT3) mutated acute myeloid leukemia (AML). Patients should be fit to receive standard induction and consolidation chemotherapy.
SK	Funded	Nov 1, 2018	In combination with standard Cytarabine and Daunorubicin (or Idarubicin) induction and Cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML). Patients should be deemed fit to receive standard induction and consolidation chemotherapy.
MB	Funded	Oct 18, 2018	In combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML). Patients should be deemed to be fit to receive standard induction and consolidation chemotherapy.

© 2020 pCODR | PAN-CANADIAN ONCOLOGY DRUG REVIEW

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
ON	Funded	Oct 11, 2018	For the treatment of adult patients diagnosed with FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML) who meet ALL the following criteria: • FLT3 mutation is confirmed by an approved test; AND • Midostaurin is used as first-line for FLT3-mutated AML; AND • Midostaurin is used in combination with standard induction chemotherapy with cytarabine and daunorubicin followed by standard consolidation chemotherapy with cytarabine OR any 7+3 induction regimen containing idarubicin followed by standard consolidation chemotherapy with cytarabine.
NS	Funded	Sep 3, 2019	For the treatment of adult patients with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia when used in combination with standard cytarabine and daunorubicin (7+3) induction and cytarabine consolidation chemotherapy. Patients should be deemed fit to receive standard induction and consolidation chemotherapy.
NB	Funded	Jun 24, 2019	For the treatment of adult patients with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML) when used in combination with standard cytarabine and daunorubicin (7+3) induction and cytarabine consolidation chemotherapy. Claim Notes: • Requests for midostaurin will not be considered when used as maintenance therapy, or as part of re-induction and/or re-consolidation. • Requests for midostaurin in combination with idarubicin containing 7+3 induction and cytarabine consolidation chemotherapy will be considered. • Approval period: Up to 6 cycles (maximum of 2 cycles of induction and 4 cycles of consolidation).

© 2020 pCODR | PAN-CANADIAN ONCOLOGY DRUG REVIEW

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
NL	Funded	Dec 19, 2019	For the treatment of adult patients with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML) when used in combination with standard cytarabine and daunorubicin (7+3) induction and cytarabine consolidation chemotherapy. Claim Notes: • Requests for midostaurin will not be considered when used as maintenance therapy, or as part of re-induction and/or re-consolidation. • Requests for midostaurin in combination with idarubicin containing 7+3 induction and cytarabine consolidation chemotherapy will be considered. • Approval period: Up to 6 cycles (maximum of 2 cycles of induction and 4 cycles of consolidation).
PEI	Under provincial consideration		

Under provincial consideration means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.

© 2020 pCODR | PAN-CANADIAN ONCOLOGY DRUG REVIEW